These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4663825)

  • 41. [Present views on pathogenesis of schizophrenia].
    Spila B
    Psychiatr Pol; 1999; 33(3):377-85. PubMed ID: 10786237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Towards a muscarinic hypothesis of schizophrenia.
    Raedler TJ; Bymaster FP; Tandon R; Copolov D; Dean B
    Mol Psychiatry; 2007 Mar; 12(3):232-46. PubMed ID: 17146471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Central nervous system dopamine receptors.
    Creese I
    Adv Biochem Psychopharmacol; 1980; 21():235-42. PubMed ID: 6103649
    [No Abstract]   [Full Text] [Related]  

  • 44. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological chaperones: potential treatment for conformational diseases.
    Bernier V; Lagacé M; Bichet DG; Bouvier M
    Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline.
    Seeman P; Guan HC; Nobrega J; Jiwa D; Markstein R; Balk JH; Picetti R; Borrelli E; Van Tol HH
    Synapse; 1997 Feb; 25(2):137-46. PubMed ID: 9021894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospects for research on schizophrenia. VII. Prospects for research in schizophrenia. An overview.
    Kety SS
    Neurosci Res Program Bull; 1972 Nov; 10(4):456-67. PubMed ID: 4197573
    [No Abstract]   [Full Text] [Related]  

  • 48. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].
    Morselli PL; Rizzo M; Tognoni G
    Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589
    [No Abstract]   [Full Text] [Related]  

  • 49. [Structural and functional organization of the cerebral dopaminergic system].
    Barishpolets VV; Fedotova IuO; Sapronov NS
    Eksp Klin Farmakol; 2009; 72(3):44-9. PubMed ID: 19642593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia.
    Ohara K
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):469-74. PubMed ID: 17184889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in the neurobiology of schizophrenia.
    Miyamoto S; LaMantia AS; Duncan GE; Sullivan P; Gilmore JH; Lieberman JA
    Mol Interv; 2003 Feb; 3(1):27-39. PubMed ID: 14993436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia.
    Clow A; Jenner P; Theodorou A; Marsden CD
    Adv Biochem Psychopharmacol; 1980; 24():53-5. PubMed ID: 6105799
    [No Abstract]   [Full Text] [Related]  

  • 54. [Trace metals in the central nervous system. State of research, successes, and future prospects].
    Prange H; Prange C
    Psychiatr Neurol Med Psychol (Leipz); 1974 May; 26(5):257-68. PubMed ID: 4859177
    [No Abstract]   [Full Text] [Related]  

  • 55. [Neuromelanine and mental diseases: dysmetabolic pathogenetic theory of schizophrenia. (New trends of research)].
    Bonifacio A; Volpe S
    Riv Patol Nerv Ment; 1967; 88(1):45-82. PubMed ID: 5621266
    [No Abstract]   [Full Text] [Related]  

  • 56. Preface. Adiposopathy in cancer and (cardio)metabolic diseases: an endocrine approach - Part 1.
    Chetrite GS; Fève B
    Horm Mol Biol Clin Investig; 2014 Oct; 20(1):1-2. PubMed ID: 25460289
    [No Abstract]   [Full Text] [Related]  

  • 57. Editorial: Metabolic and Hormonal Alterations in Neuro-Psychiatric Disorders.
    Cauli O
    Endocr Metab Immune Disord Drug Targets; 2018; 18(4):287-288. PubMed ID: 29952261
    [No Abstract]   [Full Text] [Related]  

  • 58. Nephroendocrinology: When endocrinology meets nephrology.
    Lerma EV; Koch CA
    Rev Endocr Metab Disord; 2017 Mar; 18(1):1-3. PubMed ID: 28337588
    [No Abstract]   [Full Text] [Related]  

  • 59. Editorial: Autophagy in Endocrine-Metabolic Diseases Associated With Aging.
    Vaccaro MI; De Tata V; Gonzalez CD
    Front Endocrinol (Lausanne); 2020; 11():572. PubMed ID: 32973685
    [No Abstract]   [Full Text] [Related]  

  • 60. [Fractionation of steroid hormones, epinephrine and their metabolites. Metabolism of catecholamine].
    Nakano Y; Ezaki T; Sugano Y; Shinpo S; Nagayama Y
    Nihon Rinsho; 1969 Mar; 27(3):600-8. PubMed ID: 5817116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.